ELEV News

16 IPOs went public in another active week for the IPO market, led by digital physicians network Doximity (DOCS), which soared 104% in its debut. The week’s IPOs were joined by four SPACs, as well as one postponement, Chinese social networking platform Soulgate (SSR). Doximity (DOCS) priced above the range to raise...read more

Elevation Oncology, a Phase 2 biotech developing targeted therapies for cancer in genomically-defined patients, raised $100 million by offering 6.3 million shares at $16, within the range of $15 to $17. Elevation Oncology is developing monoclonal antibody therapies by identifying oncogenic drivers that are known to be predominantly mutually exclusive with other driver...read more

Elevation Oncology, a Phase 2 biotech developing targeted therapies for cancer in genomically-defined patients, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $100 million by offering 6.3 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Elevation Oncology would command a fully diluted market value of $403...read more

Elevation Oncology, a Phase 2 biotech developing monoclonal antibodies for genetically-defined cancers, filed on Friday with the SEC to raise up to $100 million in an initial public offering. Elevation Oncology is developing monoclonal antibody therapies by identifying oncogenic drivers that are known to be predominantly mutually exclusive with other driver alterations....read more